Interim report 2023
Bio-Works' 2023 Interim report highlights a continued 22% sales growth, primarily driven by the company’s portfolio of high-value products: GoBio prepacked columns, custom resin solutions and affinity resins. This reflects Bio-Works belief that the market for biological therapies continues to diversify and the need for diversified purification tools is growing rapidly. From a regional perspective, the North American and European markets both grew over 30%, while Asia declined during the period.
Discover how we continue to embrace the rapidly diversifying biotech industry, but also taking necessary action to secure the company's path to profitability.
4 Reasons to invest in Bio-Works
Get the latest
Contact - Investor relations
First North Disclaimer
First North is an alternative marketplace operated by an exchange within the NASDAQ OMX group. Companies on First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on First North may therefore be higher than investing in a company on the main market. All companies with shares traded on First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.
Nasdaq ESG Transparency Partner
Bio-Works is a certified Nasdaq ESG Transparency Partner. This certification is used by Nasdaq to signal engagement in market transparency and in raising environmental standards. The Nasdaq ESG Matrix includes data points from Environmental, Social, Corporate Governance.